RT Journal Article
SR Electronic
T1 Whole exome sequencing in the UK Biobank reveals risk gene <em>SLC2A1</em> and biological insights for major depressive disorder
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.04.21256398
DO 10.1101/2021.05.04.21256398
A1 Ruoyu Tian
A1 Tian Ge
A1 Jimmy Z. Liu
A1 Max Lam
A1 Biogen Biobank team
A1 Daniel F. Levey
A1 Joel Gelernter
A1 Murray B. Stein
A1 Ellen A. Tsai
A1 Hailiang Huang
A1 Todd Lencz
A1 Heiko Runz
A1 Chia-Yen Chen
YR 2021
UL http://medrxiv.org/content/early/2021/05/09/2021.05.04.21256398.abstract
AB Nearly two hundred common-variant depression risk loci have been identified by genome-wide association studies (GWAS)1–4. However, the impact of rare coding variants on depression remains poorly understood. Here, we present the largest to date exome analysis of depression based on 320,356 UK Biobank participants. We show that the burden of rare disruptive coding variants in loss-of-function intolerant genes is significantly associated with depression risk. Among 30 genes with false discovery rate (FDR) &lt;0.1, SLC2A1, a blood-brain barrier glucose transporter underlying GLUT1 deficiency syndrome5–7, reached exome-wide significance (P=2.96e-7). Gene-set enrichment supports neuron projection development and muscle activities2, 3 as implicated in depression. Integrating exomes with polygenic risk revealed additive contributions from common and rare variants to depression risk. The burden of rare disruptive coding variants for depression overlapped with that of developmental disorder, autism and schizophrenia. Our study provides novel insight into the contribution of rare coding variants on depression and genetic relationships across developmental and psychiatric disorders.Competing Interest StatementR.T., E.A.T, H.R. and C.C. are employees of Biogen. J.Z.L. is an employee of GlaxoSmithKline plc.Funding StatementWe did not receive any external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Collection of the UK Biobank (UKBB) data was approved by the UKBB's Research Ethics Committee. UKBB individual-level, phenotypic data and whole exome sequencing data used in the present work were obtained under application ID 26041. The complete whole exome sequencing data used in this study will be publicly available once the embargoes have lifted (expected 2021). Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea, the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) approved the FinnGen study protocol Nr HUS/990/2017. The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019, THL/1524/5.05.00/2020, and THL/2364/14.02/2020), Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020 and Statistics Finland (permit numbers: TK-53-1041-17 and TK-53-90-20). The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 6 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, BB2020_1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154, Biobank Borealis of Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018, Finnish Clinical Biobank Tampere MH0004, Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001. Meta-analysis of depression by PGC (without UK Biobank and 23andme participants) is available at https://www.med.unc.edu/pgc/download-results/mdd/. Summary statistics of GWAS on individuals with European ancestry from Million Veteran Program (MVP) cohort was obtained through MVP Project Proposal MVP200097. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll phenotypic and genotypic data for the UK Biobank are available to researchers under data access request from the UK Biobank data access process (https://www.ukbiobank.ac.uk/enable-your-research/register). 454,787 whole exome sequencing data is not publicly available yet. Depression GWAS summary statistics from FinnGen Release 6 is not publicly available. Meta-analysis of depression by PGC (without UK Biobank and 23andme participants) is available at https://www.med.unc.edu/pgc/download-results/mdd/. Summary statistics of GWAS on individuals with European ancestry from Million Veteran Program (MVP) cohort was obtained through MVP Project Proposal MVP200097. pLoF Metrics is available at https://storage.googleapis.com/gcp-public-data--gnomad/release/2.1.1/constraint/gnomad.v2.1.1.lof_metrics.by_gene.txt.bgz. eQTLGen cis-eQTL summary statistics is available at https://www.eqtlgen.org/. Human protein atlas is available at https://www.proteinatlas.org/humanproteome/brain/human+brain. Drug gene interaction database is available at https://www.dgidb.org/. https://www.ukbiobank.ac.uk/enable-your-research/register https://www.med.unc.edu/pgc/download-results/mdd/ https://storage.googleapis.com/gcp-public-data--gnomad/release/2.1.1/constraint/gnomad.v2.1.1.lof_metrics.by_gene.txt.bgz https://www.eqtlgen.org/ https://www.proteinatlas.org/humanproteome/brain/human+brain https://www.dgidb.org/